User Tools

Site Tools


research:angioedema

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
Last revision Both sides next revision
research:angioedema [2016/05/03 02:56]
jduke
research:angioedema [2017/04/17 02:03]
jduke
Line 7: Line 7:
 **Rationale:​** The Food and Drug Administration (FDA) has [[http://​www.fda.gov/​Drugs/​GuidanceComplianceRegulatoryInformation/​Surveillance/​AdverseDrugEffects/​ucm491645.htm|recently announced]] that they are evaluating the need for regulatory action regarding a potential association between exposure to the anti-seizure drug Keppra and angioedema. OHDSI seeks to support evidence generation for questions of importance to FDA and other stakeholders seeking to protect and promote the public'​s health. **Rationale:​** The Food and Drug Administration (FDA) has [[http://​www.fda.gov/​Drugs/​GuidanceComplianceRegulatoryInformation/​Surveillance/​AdverseDrugEffects/​ucm491645.htm|recently announced]] that they are evaluating the need for regulatory action regarding a potential association between exposure to the anti-seizure drug Keppra and angioedema. OHDSI seeks to support evidence generation for questions of importance to FDA and other stakeholders seeking to protect and promote the public'​s health.
  
-**Project Lead(s):** Jon Duke, Patrick Ryan, Marc Suchard, Martijn Schuemie+**Project Lead(s):** Jon Duke, Patrick Ryan, Marc Suchard, George Hripcsak, [?Adler], Christian Reich, Yuriy Khoma, Marie-Sophie Schwalm, Yonghui Hu, [Stanford- Juan?], Martijn Schuemie.
  
-**Coordinating Institution(s):​** Regenstrief Institute+**Coordinating Institution(s):​** Regenstrief Institute ​/ Georgia Tech
  
-** Additional Participants (currently seeking additional collaborators):​**  +**Participating Institution(s):​** ​ Regenstrief Institute, Georgia Tech, Janssen Research and Development,​ Columbia University, University of California Los Angeles, University of Texas Houston, Stanford University, QuintilesIMS.
-  * George Hripcsak +
-  +
-Any interested collaborators please contact Jon Duke at jonduke@regenstrief.org and I will be happy to add you to the collaborator list.  +
- +
-**Participating Institution(s):​** Regenstrief Institute, Janssen Research and Development,​ Columbia University, University of CaliforniaLos Angeles+
  
-**Full Protocol:** [[https://​drive.google.com/​open?id=0BxVdB7jYnXcDWndwUmxrUUtjbUk|Keppra and Angioedema Risk Protocol]]+**Full Protocol:** [[https://​drive.google.com/​file/​d/​0BzotZ5gIRvegT3Y5djBOUldzaVE/​view?usp=sharing|Keppra and Angioedema Risk Protocol]]
  
 **Initial Proposal Date:​** ​ 5/3/2016 **Initial Proposal Date:​** ​ 5/3/2016
  
-**Launch Date:​** ​TBD+**Launch Date:​** ​5/18/2016
  
-**Receive Results for Analysis Date:​**  ​TBD+**Receive Results for Analysis Date:​**  ​7/15/2016
  
-**Study Closure Date:​**  ​TBD+**Study Closure Date:​**  ​12/1/2016 (**Study closed**)
  
-**Results Submission:​** [[mailto:​jonduke@regenstrief.org|Email]] ​or SFTP+**Results Submission:​** ​Via the OHDSI Sharing module embedded in study or via [[mailto:​jonduke@regenstrief.org|Email]].
  
 </​WRAP>​ </​WRAP>​
- 
- 
-===== Customizable OHDSI-Formatted IRB ===== 
-**IRB:** [[https://​docs.google.com/​document/​d/​1ApqNkCXWpmgg5gS3OQkqD21HoIPk3qU5j4gKd2DF6kY/​edit?​usp=sharing|OHDSI Climate/​Birth Month Disease Risk Customizable IRB]] 
- 
  
  
 ===== Requirements ===== ===== Requirements =====
-**CDM:​** ​V4 or V5 (both versions fully tested)+**CDM:** V5 only
  
-**Table Accessed:​**  ​CONDITION_OCCURRENCE, CONDITION_ERA, ​CONCEPT, PERSON+**Table Accessed:​**  ​CONCEPT, CONCEPT_ANCESTOR, CONDITION_ERA, ​CONDITION_OCCURRENCE,​ DRUG_ERA, DRUG_EXPOSURE,​ MEASUREMENT,​ OBSERVATION,​ OBSERVATION_PERIOD, PERSON, PROCEDURE_OCCURRENCE,​ VISIT_OCCURRENCE
  
 **Database Dialects:** SQL Server, Postgres, Oracle **Database Dialects:** SQL Server, Postgres, Oracle
  
-**Software:​** ​SQL and +**Software:​** R (>= 3.2.2, RTools), Java 
 + 
 +**Hardware:​** Recommended 8-core, 32GB memory, 100GB free space 
 + 
 +**How to Run:** Full installation and run instructions are provided on the GitHub page below.
  
  
 ===== Code =====  ===== Code ===== 
-[[https://​github.com/​maryreginaboland/SeaWAS|GitHub code for Proposed Study SeaWAS Across OHDSI]]+[[https://​github.com/​OHDSI/​StudyProtocols/​tree/​master/KeppraAngioedema|GitHub code for Proposed Study - Keppra and Angioedema Risk]]
  
-===== Discussion =====  
-[[http://​forums.ohdsi.org/​t/​ohdsi-study-4-investigating-birth-month-disease-risk-relationships-across-the-ohdsi-network/​742/​3|SeaWAS-OHDSI Discussion Thread]] ​ 
 ===== Datasets Run =====  ===== Datasets Run ===== 
-  * Columbia University ​- CUMC/NYP +  ​* CCAE (Janssen) 
-  * Taipei Medical University +  * MDCD (Janssen) 
-  * Ajou University School of Medicine+  * MDCR (Janssen) 
 +  * Optum (Janssen) 
 +  ​* Columbia University 
 +  * IMS (French) 
 +  * IMS Ambulatory 
 +  * IMS PPLUS 
 +  * Stanford 
 +  * UT Blue Cross Blue Shield 
 +  * UT Cerner 
  
 ===== Waiting for Datasets From =====  ===== Waiting for Datasets From ===== 
-  * Stanford University +  * CPRD (Janssen) 
-  * University of Colorado + 
-  * University of California, Los Angeles + 
-  * Possibly - Children'​s Hospital of Philadelphia ​ +===== Results =====  
-  * Possibly - Erasmus University Medical Center+ 
 +Results will be posted here shortly. 
 +  
 + 
 ~~NOTOC~~ ~~NOTOC~~
research/angioedema.txt · Last modified: 2017/12/14 05:54 by schuemie